Appeal No. 2006-0819 Page 7
Application No. 09/929,862
We therefore do not find Geiger to be on point, because as noted by
appellant, that case dealt with the obviousness of the combination of three
individually known components each known to be used for the same purpose. In
this case, however, one of the references, Deninno, clearly provides a
suggestion to arrive at the claimed combination by teaching a pharmaceutical
composition comprising a CETP inhibitor and a HMG-CoA reductase inhibitor.
CONCLUSION
Because the examiner has set forth a prima facie case of obviousness,
the rejection of claims 1, 4, 5 and 8-14 under 35 U.S.C. § 103(a) as being
obvious over the combination of Deninno and Roth, is affirmed.
Page: Previous 1 2 3 4 5 6 7 8 9 10 Next
Last modified: November 3, 2007